Primer Examines TPP’s Potential Impact On Drugs’ Data Exclusivity

Brookings Institution’s “Health360”: Health Policy 101: How the Trans-Pacific Partnership Will Impact Prescription Drugs
This primer discusses biologic and biosimilar drugs and concerns over “the length of data exclusivity granted to the companies that hold the patents on these drugs” contained in the Trans-Pacific Partnership (TPP), a free trade agreement that the U.S. has been negotiating with 11 other countries (5/19).